Preparation and Characterization of Meloxicam–Myrj-52 Granules Obtained by Melt Granulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Preparation and Characterization of Meloxicam–Myrj-52 Granules Obtained by Melt Granulation
Various manufacturing techniques can improve a drug's solubility, thus increasing its bioavailability. The authors examined whether melt granulation can enhance drug solubility using meloxicam as the drug substance and myrj-52 as the binder.


Pharmaceutical Technology



Figure 6: Scanning electron microscope images of (a) pure meloxicam at 2, (b) melt granules of myrj-52 at 4, and (c) melt granules of myrj-52 at 20.
Scanning electron microscopy. Figure 6 shows SEM images of pure meloxicam and the melt granulation with myrj-52. Both photographs of melt granules clearly show granules with rough surfaces.


Figure 7: Size distribution of meloxicam granules obtained by melt granulation using myrj-52 as a meltable binder.
Production and characterization of granules. Several publications show that process variables such as mixing time, temperature, and amount of binder greatly affect the characteristics of the granules obtained by melt granulation (4, 5). Therefore, the authors performed preliminary tests to select the binder concentration and the process parameters using a placebo formulation containing only StarLac and myrj-52. When good conditions were achieved, 10% (w/w) of StarLac was replaced with meloxicam. Drug-loaded granules were obtained using the parameters described in the "Methods" section above. Figure 7 shows the granules' size distribution. The amount of fine powder (< 75 μm) and the amount of big lumps (size > 1400 μm) are less than 1% and 5 %, respectively. This finding confirms that the parameters were correct. The main fraction was 200–500 μm, and more than 70% of the granules had a size in the range of 200–750 μm.


Table III: Content of meloxicam in each granule fraction using myrj-52 as a meltable binder.
Table III shows the meloxicam content in each granule fraction. The larger the granule size was, the higher the drug loading was. In many cases, the drug content is slightly higher (10%) than the theoretical drug content. One explanation could be that the material lost during granulation was mainly the binder, which was present in the molten form after heating the mixture and could partially stick to the vessel.


Figure 8: Dissolution profiles of pure meloxicam, melt granulation (MG), physical mixture (PM), and solid dispersion (SD) of meloxicam in myrj-52.
In vitro dissolution studies. To assess whether the authors had improved the dissolution rate of melt granules containing meloxicam, in vitro dissolution profiles of MG, PM, and SD were compared with those of the pure drug (see Figure 8).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here